Physician profile
Tracy J Tacket
NPI 1487775847
$5,490.79
in general payments reported to CMS, 2019-2025
37 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $316 · 2021: $288 · 2022: $875 · 2023: $1,207 · 2024: $1,109 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,336.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,240.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $494.27 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $424.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $361.95 | 2019-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $346.59 | 2019-2025 | |
| Astellas Pharma US INC | $293.41 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $257.38 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Lilly USA, LLC | $245.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $211.37 | 2019-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.18 | 2021-2025 | Jardiance, Synjardy |
| Allergan, INC. | $160.17 | 2019 | |
| Pfizer INC. | $152.80 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $118.68 | 2020-2024 | Spravato |
| Xeris Pharmaceuticals, INC. | $107.60 | 2022-2024 | Gvoke Hypopen |
| Lundbeck LLC | $89.75 | 2024-2025 | Rexulti |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Tacket listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.